Lege Artis Medicinae

[The Hepatologist’s Dilemma]

WERLING Klára

JANUARY 21, 2004

Lege Artis Medicinae - 2004;14(01)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[A NEW DISCIPLINE IN THE CENTER OF MEDICAL RESEARCH AND CLINICAL PRACTICE - THOUGHTS ON BIOINFORMATICS]

FALUS ANDRÁS, BERKE Tamás, ORTUTAY Csaba Péter, SUHAI György

[Bioinformatics is one of the most important element of genomic research revolutionising biomedical science. This review describes the phenomena of genomic variance and comparative genomics. Briefly, the review summarises the identification procedure of new genes and gene expression patterns highly important in diagnostics. Bioinformatic procedures make possible the rapid detection of pathogens and have principal role in molecular drug design technologies.]

Lege Artis Medicinae

[Medical care in Hungary - 2004]

FRENKL Róbert

Lege Artis Medicinae

[CURE]

MATOS Lajos

Lege Artis Medicinae

[GENDER ASSOCIATED DIFFERENCES IN THE PROGRESSION OF RENAL DISEASES]

MÜLLER Veronika, SZABÓ Attila

[Increasing evidence suggests an important role of gender in the incidence, progression and different therapeutic possibilities of several diseases. Recent data demonstrated gender associated differences in the development and progression of chronic renal diseases. Present work reviews sexual dimorphism in different chronic renal diseases, summarizes underlying pathophysiological processes and therapeutic possibilities focusing on the role of gender. New evidences may present the base of gender based therapies in the future.]

Lege Artis Medicinae

[LEGIONNAIRES’ DISEASE]

ROJKÓ Lívia

[Legionellae are important causative agents of nosocomial and community acquired pneumonias, the prevalence varying between 2-30%. The number of verified infections are increasing from year to year, which may be the consequence of the more sensitive and commonly applied laboratorical methods or can be explained by the spread of non-natural living environments created by humans. The outcome of Legionella infections are strongly determined by the host immune system, the comorbidities, the time to the diagnosis made and the initiated treatment. This review focuses on the various clinical manifestations of the Legionella infections, and summarises the diagnostic criteria and therapeutic methods in practice.]

All articles in the issue

Related contents

Clinical Neuroscience

[Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke]

PÁSZTOR Máté, BERECZKI Dániel, SZAKÁCS ZOLTÁN, MAY Zsolt

[Introduction - Expanding indications have resulted in an increasing number of patients taking novel oral anticoagulants, posing a major treatment dilemma in acute ischemic stroke. Case presentation - We present a successful intravenous thrombolysis in a dabigatran-treated patient with acute ischemic stroke after the administration of idarucizumab. Discussion - According to current guidelines, systemic thrombolysis is contraindicated under treatment with novel oral anticoagulants (taken within 48 hours). In this scenario, idarucizumab offers a solution by reversing the anticoagulant effect of dabigatran. Conclusion - Although there have only been case reports published so far, the dabigatran-antidote idarucizumab seems to give new therapeutic opportunities in the treatment of acute ischemic stroke.]

Hungarian Radiology

[Evaluation of cystic renal masses with MDCT]

BATA Pál, MIKUSI Regina, KARLINGER Kinga, BÉRCZI Viktor, SZENDRŐI Attila, ROMICS Imre

[Modern CT and MRI scanners can give an exact and rapid diagnosis in the case of most cystic renal masses. Dilemma in their diagnosis is whether or not the changes need surgical intervention. The question of follow-up is decided with the use of the Bosniak classification. To characterize the cystic changes excellent quality, multiphasic MDCT examination is necessary with the following parameters: 80-120 mls. of non-ionic iodinated intravenous contrast material given with an injector at 3 ml/sec flow-rate with saline flush technique, unenhanced and post-contrast scans obtained at 35 and 70 seconds, with more scans at 120-300 seconds, as deemed necessary. A collimation of 16x1.5 mm with an overlap of 50% should be aimed for. Through the primary data we perform a reconstruction of 2 mm, with an option to create volume-rendered image sin the post-processing phase, as necessary. With the help of this CT protocol we can measure the different criterions of Bosniak classification in the cystic masses like minimal, smooth or irregular wall thickening, with or without enhancement. We can recognize hairline thin or thickened septa, fine or irregular (thick or nodular) calcifications, solid component with or without contrast enhancement. Using these criteria each cystic mass can be assigned to a Bosniak cystic category (I, II, IIF, III and IV)]

Lege Artis Medicinae

[Perioperative management of patients with coronary stent in case of interventions other than cardiac surgery - Part I. - Perioperative treatment of patients with coronary stent]

ZIMA Endre, MEZŐFI Miklós, BECKER Dávid, SZABÓ György, MERKELY Béla, PÉNZES István

[Percutaneous coronary intervention (PCI) is meant to optimalise cardiac status, that is, short-term and long-term outcomes. It is known from large Western databases that stent implantation is performed in 77-85% of coronary interventions, which means hundreds of thousands of new patients with stent every year. The great majority of these patients has to take platelet aggregation inhibitors, namely acetylsalicylic acid and thienopyridin, most often clopidrogel. It presents a major therapeutic dilemma when these patients require noncardiac surgery. First, surgery should be performed with the least possible blood loss, which would be optimal if the platelet aggregation inhibitor therapy - that is indispensable for a certain period because of the stent - was suspended. Second, stent thrombosis has to be avoided, which can only be achieved if platelet aggregation inhibitor therapy is continued. The aim of our paper is to summarise the current guidelines and the risk estimation on the basis of our current knowledge in the perioperative management of patients with coronary stent. In the first part, we overview the platelet aggregation inhibitor agents, their mechanisms of effect, stent types and the minimal therapeutic period to be strictly observed, which depends on the type of stent.]

Clinical Neuroscience

[Dilemma of further therapeutic step in RRMS in case of ineffectivity of first line treatment: fingolimod or natalizumab?]

LOVAS Gábor

Lege Artis Medicinae

[Pairs in Pairs A Discussion with Internist-Hepatologist Professor Alajos Pár]

NEMESÁNSZKY Elemér